WP
Woodline Partners Portfolio holdings
AUM
$18.9B
1-Year Return
23.37%
This Quarter Return
-5.06%
1 Year Return
+23.37%
3 Year Return
+125.78%
5 Year Return
+185.63%
10 Year Return
–
AUM
$6.02B
AUM Growth
-$804M
(-12%)
Cap. Flow
-$363M
Cap. Flow
% of AUM
-6.02%
Top 10 Holdings %
Top 10 Hldgs %
15.41%
Holding
911
New
217
Increased
113
Reduced
99
Closed
202
Top Buys
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$107M |
| 2 |
ZNGA
ZYNGA INC. CL A COMMON
ZNGA
|
$102M |
| 3 |
Boston Scientific
BSX
|
$81.1M |
| 4 |
Lam Research
LRCX
|
$78.9M |
| 5 |
Merck
MRK
|
$69.7M |
Top Sells
| 1 |
AbbVie
ABBV
|
$145M |
| 2 |
ASML
ASML
|
$119M |
| 3 |
Microsoft
MSFT
|
$82.9M |
| 4 |
Qorvo
QRVO
|
$81.7M |
| 5 |
Eli Lilly
LLY
|
$75.9M |
Sector Composition
| 1 | Healthcare | 39.48% |
| 2 | Technology | 29.86% |
| 3 | Industrials | 8.84% |
| 4 | Communication Services | 6.13% |
| 5 | Financials | 6.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Zymeworks
ZYME
$1.14B
| $14.5M | 0.24% |
2,216,062
+957,661
| +76% | +$6.27M |
|
127
Textron
TXT
$14.5B
| $14.5M | 0.24% |
194,927
-47,277
| -20% | -$3.52M |
|
|
AVDL
128
Avadel Pharmaceuticals
AVDL
$1.53B
| $14.5M | 0.23% |
2,116,029
-146,973
| -6% | -$1M |
|
129
Charter Communications
CHTR
$35.7B
| $14.2M | 0.23% |
+26,085
| New | +$14.2M |
|
|
SAIL
130
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
| $14.2M | 0.23% |
276,528
-24,659
| -8% | -$1.26M |
|
131
Outset Medical
OM
$249M
| $14.1M | 0.23% |
20,653
+5,253
| +34% | +$3.58M |
|
132
Keros Therapeutics
KROS
$633M
| $14M | 0.23% |
257,200
+180,988
| +237% | +$9.84M |
|
133
Electronic Arts
EA
$42.2B
| $14M | 0.23% |
110,464
-235,077
| -68% | -$29.7M |
|
134
Protagonist Therapeutics
PTGX
$3.77B
| $13.9M | 0.23% |
588,694
+95,707
| +19% | +$2.27M |
|
135
Henry Schein
HSIC
$8.42B
| $13.9M | 0.23% |
159,463
-470,352
| -75% | -$41M |
|
136
Thermo Fisher Scientific
TMO
$186B
| $13.7M | 0.22% |
23,271
+5,318
| +30% | +$3.14M |
|
137
Nice
NICE
$8.67B
| $13.7M | 0.22% |
+62,488
| New | +$13.7M |
|
138
Exelixis
EXEL
$10.2B
| $13.6M | 0.22% |
601,800
| – | – |
|
|
VG
139
DELISTED
Vonage Holdings Corporation
VG
| $13.6M | 0.22% |
670,197
+121,497
| +22% | +$2.47M |
|
140
CrowdStrike
CRWD
$105B
| $13.5M | 0.22% |
+59,513
| New | +$13.5M |
|
|
SWTX
141
DELISTED
SpringWorks Therapeutics
SWTX
| $13.2M | 0.21% |
233,210
-9,190
| -4% | -$519K |
|
142
Ascendis Pharma
ASND
$12.5B
| $13.1M | 0.21% |
112,012
-112,437
| -50% | -$13.2M |
|
143
Intel
INTC
$107B
| $13.1M | 0.21% |
+264,284
| New | +$13.1M |
|
144
Penumbra
PEN
$11B
| $13M | 0.21% |
58,345
-14,287
| -20% | -$3.17M |
|
145
Flex
FLEX
$20.8B
| $12.9M | 0.21% |
919,734
-894,406
| -49% | -$12.5M |
|
146
HealthEquity
HQY
$7.88B
| $12.8M | 0.21% |
190,180
+127,188
| +202% | +$8.58M |
|
147
Zai Lab
ZLAB
$3.42B
| $12.8M | 0.21% |
+291,517
| New | +$12.8M |
|
148
Sana Biotechnology
SANA
$752M
| $12.8M | 0.21% |
1,551,940
+1,069,234
| +222% | +$8.83M |
|
149
PROS Holdings
PRO
$746M
| $12.7M | 0.21% |
+381,187
| New | +$12.7M |
|
150
Theravance Biopharma
TBPH
$703M
| $12.7M | 0.21% |
1,326,653
+751,540
| +131% | +$7.18M |
|